{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-087461","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.648263+00:00","generated_at":"2026-05-17T06:40:33.384884+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors for up to $15M in milestones","bullets":["Acquires frunexian (Phase 2-ready IV FXIa) and EP-7327 (IND-ready oral FXIa) from eXIthera.","Total contingent milestone payments up to $15M plus royalties on global sales; $50K cash paid at closing.","Deal closed September 12, 2025; Cadrenal now sole developer of both a VKA (tecarfarin) and FXIa inhibitors.","Plans Phase 2 study for frunexian in complex cardiac surgery with first patient expected in 1Q27.","eXIthera to receive 2% royalty on net sales outside China and 50% of sublicense royalties from Haisco."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-087461","json":"https://secwatch.observer/filing/0001213900-25-087461.json","markdown":"https://secwatch.observer/filing/0001213900-25-087461.md","text":"https://secwatch.observer/filing/0001213900-25-087461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025087461/0001213900-25-087461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025087461/ea0257138-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:40:33.384884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}